# Paolo M Comoglio

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 286 papers | 26,558 citations | 86 h-index | 157 g-index |
| 294 ext. papers | 28,511 ext. citations | 10.9 avg, IF | 6.76 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 286 | hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of MET-addicted cancers.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 112 | 12.8 | 0 |
| 285 | MET14 promotes a ligand-dependent, AKT-driven invasive growth. *Life Science Alliance*, **2022**, 5, e202201409 | 5.8 | 0 |
| 284 | MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 1 |
| 283 | Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. *Nature Communications*, **2021**, 12, 2498 | 17.4 | 4 |
| 282 | Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor-dependent mechanisms. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2235-2247 | 15.4 | 1 |
| 281 | HGF and MET: From Brain Development to Neurological Disorders. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 683609 | 5.7 | 9 |
| 280 | ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. *Cell Reports*, **2021**, 36, 109455 | 10.6 | 2 |
| 279 | A receptor-antibody hybrid hampering MET-driven metastatic spread. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 32 | 12.8 | 2 |
| 278 | Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report. *EMBO Molecular Medicine*, **2020**, 12, e11756 | 12 | 8 |
| 277 | ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 91 |
| 276 | Met inhibition revokes IFN induction of PD-1 ligands in MET-amplified tumours. *British Journal of Cancer*, **2019**, 120, 527-536 | 8.7 | 26 |
| 275 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. *Nature Reviews Cancer*, **2018**, 18, 341-358 | 31.3 | 152 |
| 274 | Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy. *International Journal of Cancer*, **2018**, 143, 1774-1785 | 7.5 | 8 |
| 273 | A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. *Clinical Cancer Research*, **2018**, 24, 807-820 | 12.9 | 18 |
| 272 | The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers. *International Journal of Cancer*, **2018**, 143, 2838-2848 | 7.5 | 11 |
| 271 | Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. *Human Mutation*, **2018**, 39, 371-377 | 4.7 | 14 |
| 270 | MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 14 |

| | | | |
|---|---|---|---|
| 269 | Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 10058-10063 | 11.5 | 11 |
| 268 | Discovery and Function of the HGF/MET and the MSP/RON Kinase Signaling Pathways in Cancer **2018**, 1-43 | | 1 |
| 267 | MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin. *EBioMedicine*, **2017**, 24, 34-42 | 8.8 | 4 |
| 266 | Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. *Stem Cells*, **2017**, 35, 2218-2228 | 5.8 | 30 |
| 265 | Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. *Oncogene*, **2017**, 36, 1200-1210 | 9.2 | 24 |
| 264 | Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. *Oncotarget*, **2017**, 8, 38193-38213 | 3.3 | 16 |
| 263 | Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. *Lancet Oncology, The*, **2016**, 17, 1386-1395 | 21.7 | 251 |
| 262 | Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals. *BMC Biology*, **2016**, 14, 5 | 7.3 | 18 |
| 261 | Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. *Journal of Molecular and Cellular Cardiology*, **2016**, 93, 84-97 | 5.8 | 6 |
| 260 | C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. *Oncotarget*, **2016**, 7, 45525-45537 | 3.3 | 21 |
| 259 | Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. *Cancer Research*, **2016**, 76, 5019-29 | 10.1 | 16 |
| 258 | MET inhibition overcomes radiation resistance of glioblastoma stem-like cells. *EMBO Molecular Medicine*, **2016**, 8, 550-68 | 12 | 54 |
| 257 | Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. *Molecular Oncology*, **2016**, 10, 938-48 | 7.9 | 10 |
| 256 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 738-746 | 21.7 | 533 |
| 255 | IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. *Science Translational Medicine*, **2015**, 7, 272ra12 | 17.5 | 79 |
| 254 | Targeting the oncogenic Met receptor by antibodies and gene therapy. *Oncogene*, **2015**, 34, 1883-9 | 9.2 | 33 |
| 253 | TNF-□promotes invasive growth through the MET signaling pathway. *Molecular Oncology*, **2015**, 9, 377-88 | 7.9 | 33 |
| 252 | Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. *Molecular Oncology*, **2015**, 9, 1760-72 | 7.9 | 15 |

| | | | |
|---|---|---|---|
| 251 | Activation of RAS family members confers resistance to ROS1 targeting drugs. *Oncotarget*, **2015**, 6, 5182-94 | 5.5 | 62 |
| 250 | MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. *British Journal of Haematology*, **2014**, 164, 841-50 | 4.5 | 18 |
| 249 | An Open-cell trial to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. *Molecular Oncology*, **2014**, 8, 378-88 | 7.9 | 6 |
| 248 | Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. *Molecular Oncology*, **2014**, 8, 1561-74 | 7.9 | 14 |
| 247 | The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. *International Journal of Cancer*, **2014**, 135, 2305-16 | 7.5 | 34 |
| 246 | MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. *Cancer Research*, **2014**, 74, 1857-69 | 10.1 | 103 |
| 245 | Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. *Journal of Molecular Medicine*, **2014**, 92, 65-76 | 5.5 | 8 |
| 244 | MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. *Cancer Research*, **2014**, 74, 3647-51 | 10.1 | 28 |
| 243 | Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. *Cell Death and Disease*, **2014**, 5, e1185 | 9.8 | 50 |
| 242 | MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. *Current Opinion in Cell Biology*, **2014**, 31, 98-105 | 9 | 31 |
| 241 | Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. *Cancer Research*, **2014**, 74, 6598-609 | 10.1 | 50 |
| 240 | The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. *Cancer Research*, **2013**, 73, 3193-9 | 10.1 | 46 |
| 239 | Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. *Lancet Respiratory Medicine,the*, **2013**, 1, 251-61 | 35.1 | 57 |
| 238 | Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. *Oncogene*, **2013**, 32, 1428-40 | 9.2 | 49 |
| 237 | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discovery*, **2013**, 3, 658-73 | 24.4 | 489 |
| 236 | S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. *Molecular Cancer Therapeutics*, **2013**, 12, 1749-62 | 6.1 | 69 |
| 235 | Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. *Journal of Clinical Investigation*, **2013**, 123, 5411-5411 | 15.9 | 78 |
| 234 | A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. *International Journal of Cancer*, **2012**, 130, 1357-66 | 7.5 | 17 |

| | | | |
|---|---|---|---|
| 233 | The MET oncogene is a functional marker of a glioblastoma stem cell subtype. *Cancer Research*, **2012**, 72, 4537-50 | 10.1 | 104 |
| 232 | Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. *Clinical Cancer Research*, **2012**, 18, 2515-25 | 12.9 | 152 |
| 231 | MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. *Clinical Cancer Research*, **2012**, 18, 737-47 | 12.9 | 104 |
| 230 | A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discovery*, **2011**, 1, 508-23 | 24.4 | 668 |
| 229 | Ron kinase transphosphorylation sustains MET oncogene addiction. *Cancer Research*, **2011**, 71, 1945-55 | 10.1 | 61 |
| 228 | Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. *Clinical and Experimental Metastasis*, **2011**, 28, 793-802 | 4.7 | 40 |
| 227 | MET mutations in cancers of unknown primary origin (CUPs). *Human Mutation*, **2011**, 32, 44-50 | 4.7 | 57 |
| 226 | Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 14240-5 | 11.5 | 100 |
| 225 | Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. *Journal of the National Cancer Institute*, **2011**, 103, 645-61 | 9.7 | 261 |
| 224 | Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. *Cancer Research*, **2011**, 71, 3132-41 | 10.1 | 108 |
| 223 | Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. *Clinical Cancer Research*, **2011**, 17, 3146-56 | 12.9 | 101 |
| 222 | Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. *Oncogene*, **2010**, 29, 5286-98 | 9.2 | 20 |
| 221 | MET signalling: principles and functions in development, organ regeneration and cancer. *Nature Reviews Molecular Cell Biology*, **2010**, 11, 834-48 | 48.7 | 884 |
| 220 | The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. *Journal of Biological Chemistry*, **2010**, 285, 38756-64 | 5.4 | 41 |
| 219 | Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. *Journal of Biological Chemistry*, **2010**, 285, 36149-57 | 5.4 | 67 |
| 218 | MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. *Cancer Research*, **2010**, 70, 7580-90 | 10.1 | 144 |
| 217 | Inhibition of Src impairs the growth of met-addicted gastric tumors. *Clinical Cancer Research*, **2010**, 16, 3933-43 | 12.9 | 36 |
| 216 | A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. *Journal of Biological Chemistry*, **2010**, 285, 26335-40 | 5.4 | 51 |

| | | | |
|---|---|---|---|
| 215 | Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. *Molecular Cancer*, **2010**, 9, 121 | 42.1 | 83 |
| 214 | Targeting the MET oncogene in cancer and metastases. *Expert Opinion on Investigational Drugs*, **2010**, 19, 1381-94 | 5.9 | 41 |
| 213 | The Met oncogene and basal-like breast cancer: another culprit to watch out for?. *Breast Cancer Research*, **2010**, 12, 208 | 8.3 | 56 |
| 212 | Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. *Journal of Clinical Investigation*, **2010**, 120, 2684-98 | 15.9 | 123 |
| 211 | The Fathers of Italian Histology. *European Journal of Histochemistry*, **2009**, 51, 1 | 2.1 | 4 |
| 210 | The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. *Molecular Biology of the Cell*, **2009**, 20, 642-57 | 3.5 | 49 |
| 209 | Only a subset of Met-activated pathways are required to sustain oncogene addiction. *Science Signaling*, **2009**, 2, ra80 | 8.8 | 76 |
| 208 | Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. *Human Mutation*, **2009**, 30, 1167-74 | 4.7 | 34 |
| 207 | Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. *Oncogene*, **2009**, 28, 1421-31 | 9.2 | 75 |
| 206 | Genetic link between cancer and thrombosis. *Journal of Clinical Oncology*, **2009**, 27, 4827-33 | 2.2 | 55 |
| 205 | Only a subset of Met-activated pathways are required to sustain oncogene addiction. *Science Signaling*, **2009**, 2, er11 | 8.8 | 19 |
| 204 | Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. *Journal of Clinical Investigation*, **2009**, 119, 865-75 | 15.9 | 52 |
| 203 | Silencing the MET oncogene leads to regression of experimental tumors and metastases. *Oncogene* , **2008**, 27, 684-93 | 9.2 | 113 |
| 202 | Met-driven invasive growth involves transcriptional regulation of Arhgap12. *Oncogene*, **2008**, 27, 5590-8 | 9.2 | 26 |
| 201 | Drug development of MET inhibitors: targeting oncogene addiction and expedience. *Nature Reviews Drug Discovery*, **2008**, 7, 504-16 | 64.1 | 656 |
| 200 | Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. *Journal of Experimental Medicine*, **2008**, 205, 1673-85 | 16.6 | 200 |
| 199 | "Active" cancer immunotherapy by anti-Met antibody gene transfer. *Cancer Research*, **2008**, 68, 9176-83 | 10.1 | 32 |
| 198 | A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. *Journal of Biological Chemistry*, **2008**, 283, 21267-77 | 5.4 | 95 |

| | | | |
|---|---|---|---|
| 197 | The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. *Journal of Experimental Medicine*, **2008**, 205, 1155-71 | 16.6 | 79 |
| 196 | MicroRNAs impair MET-mediated invasive growth. *Cancer Research*, **2008**, 68, 10128-36 | 10.1 | 156 |
| 195 | Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. *Annals of Oncology*, **2008**, 19, 1605-12 | 10.3 | 74 |
| 194 | Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. *PLoS ONE*, **2008**, 3, e3223 | 3.7 | 31 |
| 193 | The Met tyrosine kinase receptor in development and cancer. *Cancer and Metastasis Reviews*, **2008**, 27, 85-94 | 9.6 | 257 |
| 192 | Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 1857-67 | 8.8 | 80 |
| 191 | Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. *Hepatology*, **2008**, 47, 2010-25 | 11.2 | 14 |
| 190 | The MET receptor tyrosine kinase in invasion and metastasis. *Journal of Cellular Physiology*, **2007**, 213, 316-25 | 7 | 217 |
| 189 | Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. *BMC Developmental Biology*, **2007**, 7, 55 | 3.1 | 60 |
| 188 | A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. *Oncogene*, **2007**, 26, 1078-87 | 9.2 | 97 |
| 187 | Genetic targeting of the kinase activity of the Met receptor in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 11412-7 | 11.5 | 35 |
| 186 | Oncogenes, Cancer and Hemostasis **2007**, 1-15 | | 1 |
| 185 | p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. *International Journal of Cancer*, **2006**, 118, 2981-90 | 7.5 | 37 |
| 184 | Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5090-5 | 11.5 | 137 |
| 183 | MET overexpression turns human primary osteoblasts into osteosarcomas. *Cancer Research*, **2006**, 66, 4750-7 | 10.1 | 106 |
| 182 | The Met pathway: master switch and drug target in cancer progression. *FASEB Journal*, **2006**, 20, 1611-21 | 6.9 | 110 |
| 181 | Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. *Journal of Cell Biology*, **2006**, 175, 993-1003 | 7.3 | 101 |
| 180 | Scatter Factors in Tumor Progression **2006**, 111-142 | | |

| | | | |
|---|---|---|---|
| 179 | Invasive growth: a MET-driven genetic programme for cancer and stem cells. *Nature Reviews Cancer* , **2006**, 6, 637-45 | 31.3 | 440 |
| 178 | Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. *Molecular Cell*, **2005**, 20, 881-90 | 17.6 | 282 |
| 177 | Cancer therapy: can the challenge be MET?. *Trends in Molecular Medicine*, **2005**, 11, 284-92 | 11.5 | 200 |
| 176 | Sema4D induces angiogenesis through Met recruitment by Plexin B1. *Blood*, **2005**, 105, 4321-9 | 2.2 | 194 |
| 175 | TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. *Oncogene*, **2005**, 24, 3002-10 | 9.2 | 101 |
| 174 | The MET oncogene drives a genetic programme linking cancer to haemostasis. *Nature*, **2005**, 434, 396-400 | 30.4 | 206 |
| 173 | Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. *Cancer Research*, **2005**, 65, 10674-9 | 10.1 | 65 |
| 172 | A functional role for hemostasis in early cancer development. *Cancer Research*, **2005**, 65, 8579-82 | 10.1 | 36 |
| 171 | Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. *Cancer Research*, **2005**, 65, 6167-77 | 10.1 | 98 |
| 170 | Negative feedback regulation of Met-dependent invasive growth by Notch. *Molecular and Cellular Biology*, **2005**, 25, 3982-96 | 4.8 | 47 |
| 169 | p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. *Journal of Cell Science*, **2005**, 118, 4689-700 | 5.3 | 84 |
| 168 | Invasive growth: a genetic program. *International Journal of Developmental Biology*, **2004**, 48, 451-6 | 1.9 | 31 |
| 167 | Hepatocyte Growth Factor/Scatter Factor Receptor **2004**, 367-371 | | |
| 166 | Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. *Cancer Research*, **2004**, 64, 1744-50 | 10.1 | 44 |
| 165 | Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. *Cancer Research*, **2004**, 64, 5154-61 | 10.1 | 89 |
| 164 | Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. *Journal of Biological Chemistry*, **2004**, 279, 28970-8 | 5.4 | 93 |
| 163 | To move or not to move? Semaphorin signalling in cell migration. *EMBO Reports*, **2004**, 5, 356-61 | 6.5 | 132 |
| 162 | Plexin-B3 is a functional receptor for semaphorin 5A. *EMBO Reports*, **2004**, 5, 710-4 | 6.5 | 116 |

| | | | |
|---|---|---|---|
| 161 | Interplay between scatter factor receptors and B plexins controls invasive growth. *Oncogene*, **2004**, 23, 5131-7 | 9.2 | 151 |
| 160 | Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. *Cancer Cell*, **2004**, 6, 61-73 | 24.3 | 261 |
| 159 | An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. *Journal of Clinical Investigation*, **2004**, 114, 1418-32 | 15.9 | 79 |
| 158 | Functional regulation of semaphorin receptors by proprotein convertases. *Journal of Biological Chemistry*, **2003**, 278, 10094-101 | 5.4 | 58 |
| 157 | Interactions between growth factor receptors and adhesion molecules: breaking the rules. *Current Opinion in Cell Biology*, **2003**, 15, 565-71 | 9 | 215 |
| 156 | Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell*, **2003**, 3, 347-61 | 24.3 | 1111 |
| 155 | Tyrosine kinase signal specificity: lessons from the HGF receptor. *Trends in Biochemical Sciences*, **2003**, 28, 527-33 | 10.3 | 146 |
| 154 | Hepatocyte growth factor and its receptor are required for malaria infection. *Nature Medicine*, **2003** , 9, 1363-9 | 50.5 | 119 |
| 153 | The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. *Experimental Cell Research*, **2003**, 288, 382-9 | 4.2 | 97 |
| 152 | Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. *Journal of Biological Chemistry*, **2003**, 278, 29352-8 | 5.4 | 37 |
| 151 | Feline STK gene expression in mammary carcinomas. *Oncogene*, **2002**, 21, 1785-90 | 9.2 | 26 |
| 150 | The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. *Nature*, **2002**, 416, 187-90 | 50.4 | 380 |
| 149 | An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. *Nature Biotechnology*, **2002**, 20, 488-95 | 44.5 | 22 |
| 148 | The semaphorin 4D receptor controls invasive growth by coupling with Met. *Nature Cell Biology*, **2002**, 4, 720-4 | 23.4 | 361 |
| 147 | Scatter-factor and semaphorin receptors: cell signalling for invasive growth. *Nature Reviews Cancer*, **2002**, 2, 289-300 | 31.3 | 630 |
| 146 | A differentiation switch for genetically modified hepatocytes. *FASEB Journal*, **2002**, 16, 120-2 | 0.9 | 12 |
| 145 | Series Introduction: Invasive growth: from development to metastasis. *Journal of Clinical Investigation*, **2002**, 109, 857-862 | 15.9 | 148 |
| 144 | Invasive growth: from development to metastasis. *Journal of Clinical Investigation*, **2002**, 109, 857-62 | 15.9 | 65 |

| | | | |
|---|---|---|---|
| 143 | Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. *Cancer Research*, **2002**, 62, 7025-30 | 10.1 | 81 |
| 142 | Scatter factors and invasive growth. *Seminars in Cancer Biology*, **2001**, 11, 153-65 | 12.7 | 100 |
| 141 | A gene trap vector system for identifying transcriptionally responsive genes. *Nature Biotechnology*, **2001**, 19, 579-82 | 44.5 | 59 |
| 140 | Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. *Oncogene*, **2001**, 20, 156-66 | 9.2 | 39 |
| 139 | Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness. *Oncogene*, **2001**, 20, 5493-502 | 9.2 | 5 |
| 138 | Macrophage stimulating protein is a novel neurotrophic factor. *Molecular Biology of the Cell*, **2001**, 12, 1341-52 | 3.5 | 24 |
| 137 | Apoptosis enhancement by the HIV-1 Nef protein. *Journal of Immunology*, **2001**, 166, 81-8 | 5.3 | 83 |
| 136 | Hepatocyte growth factor is a regulator of monocyte-macrophage function. *Journal of Immunology*, **2001**, 166, 1241-7 | 5.3 | 102 |
| 135 | Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. *Journal of Biological Chemistry*, **2001**, 276, 46632-8 | 5.4 | 28 |
| 134 | The transmembrane protein Off-track associates with Plexins and functions downstream of Semaphorin signaling during axon guidance. *Neuron*, **2001**, 32, 53-62 | 13.9 | 140 |
| 133 | A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. *Cell*, **2001**, 107, 643-54 | 56.2 | 376 |
| 132 | Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. *Current Drug Targets*, **2001**, 2, 41-55 | 3 | 55 |
| 131 | HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. *FASEB Journal*, **2000**, 14, 1629-1640 | 0.9 | 88 |
| 130 | Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. *International Journal of Cancer*, **2000**, 89, 286-292 | 7.5 | 54 |
| 129 | Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. *Oncogene*, **2000**, 19, 1509-18 | 9.2 | 145 |
| 128 | Signalling by semaphorin receptors: cell guidance and beyond. *Trends in Cell Biology*, **2000**, 10, 377-83 | 18.3 | 298 |
| 127 | Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. *Endocrine Pathology*, **2000**, 11, 19-30 | 4.2 | 60 |
| 126 | HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. *FASEB Journal*, **2000**, 14, 1629-40 | 0.9 | 68 |

| | | | |
|---|---|---|---|
| 125 | Plexins, Semaphorins, and Scatter Factor Receptors: A Common Root for Cell Guidance Signals?. *IUBMB Life*, **1999**, 48, 477-482 | 4.7 | 30 |
| 124 | A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. *Journal of Biological Chemistry*, **1999**, 274, 29274-81 | 5.4 | 50 |
| 123 | Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. *Oncogene*, **1999**, 18, 1139-46 | 9.2 | 69 |
| 122 | Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. *Oncogene*, **1999**, 18, 4275-81 | 9.2 | 52 |
| 121 | Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. *Oncogene*, **1999**, 18, 5221-31 | 9.2 | 129 |
| 120 | Plexins, semaphorins, and scatter factor receptors: a common root for cell guidance signals?. *IUBMB Life*, **1999**, 48, 477-82 | 4.7 | 34 |
| 119 | Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. *International Journal of Cancer*, **1999**, 82, 640-3 | 7.5 | 70 |
| 118 | Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. *Journal of Pathology*, **1999**, 189, 570-5 | 9.4 | 27 |
| 117 | HGF: a multifunctional growth factor controlling cell scattering. *International Journal of Biochemistry and Cell Biology*, **1999**, 31, 1357-62 | 5.6 | 132 |
| 116 | Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell*, **1999**, 99, 71-80 | 56.2 | 916 |
| 115 | Unified nomenclature for the semaphorins/collapsins. Semaphorin Nomenclature Committee. *Cell*, **1999**, 97, 551-2 | 56.2 | 364 |
| 114 | Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. *Experimental Cell Research*, **1999**, 253, 88-99 | 4.2 | 55 |
| 113 | C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells. *Clinical and Experimental Metastasis*, **1998**, 16, 253-65 | 4.7 | 15 |
| 112 | Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. *Nature*, **1998**, 391, 285-8 | 50.4 | 447 |
| 111 | Overexpression of the RON gene in human breast carcinoma. *Oncogene*, **1998**, 16, 2927-33 | 9.2 | 172 |
| 110 | Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. *Journal of Pathology*, **1998**, 186, 287-91 | 9.4 | 35 |
| 109 | Plexin A is a neuronal semaphorin receptor that controls axon guidance. *Cell*, **1998**, 95, 903-16 | 56.2 | 392 |
| 108 | Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14379-83 | 11.5 | 86 |

| | | | |
|---|---|---|---|
| 107 | Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. *Biochemical Journal*, **1998**, 336 ( Pt 1), 235-9 | 3.8 | 28 |
| 106 | Interactions between scatter factors and their receptors: hints for therapeutic applications. *FASEB Journal*, **1998**, 12, 1267-80 | 0.9 | 72 |
| 105 | Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2322-8 | 5.6 | 58 |
| 104 | Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. *Journal of Cell Biology*, **1997**, 138, 423-34 | 7.3 | 273 |
| 103 | A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. *Journal of Cell Biology*, **1997**, 137, 1057-68 | 7.3 | 156 |
| 102 | Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. *Cytokine and Growth Factor Reviews*, **1997**, 8, 129-42 | 17.9 | 95 |
| 101 | A point mutation in the MET oncogene abrogates metastasis without affecting transformation. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 13868-72 | 11.5 | 82 |
| 100 | Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. *Oncogene*, **1997**, 14, 705-11 | 9.2 | 46 |
| 99 | Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. *Oncogene*, **1997**, 14, 2417-23 | 9.2 | 130 |
| 98 | Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. *Oncogene*, **1997**, 15, 3103-11 | 9.2 | 116 |
| 97 | "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1997**, 1333, M41-51 | 11.2 | 20 |
| 96 | Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. *EMBO Journal*, **1997**, 16, 495-503 | 13 | 140 |
| 95 | Control of invasive growth by the HGF receptor family. *Journal of Cellular Physiology*, **1997**, 173, 183-6 | 7 | 35 |
| 94 | Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2322-2328 | 5.6 | 52 |
| 93 | Scatter factor receptors are key players in a unique multistep program leading to invasive growth. *Novartis Foundation Symposium*, **1997**, 212, 133-44; discussion 144-7 | | 6 |
| 92 | Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. *Cell*, **1996**, 87, 531-42 | 56.2 | 275 |
| 91 | A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 674-8 | 11.5 | 153 |
| 90 | The hepatocyte growth factor receptor (MET): An unconventional transducer of mitogenic and motogenic signals. *Growth Factors and Cytokines in Health and Disease*, **1996**, 1, 465-490 | | 1 |

| | | | |
|---|---|---|---|
| 89 | Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 7644-8 | 11.5 | 184 |
| 88 | Expression of Met protein in thyroid tumours. *Journal of Pathology*, **1996**, 180, 266-70 | 9.4 | 72 |
| 87 | Over-expression of hepatocyte growth factor in human Kaposi@ sarcoma. *International Journal of Cancer*, **1996**, 65, 168-72 | 7.5 | 32 |
| 86 | Overexpression of the met/HGF receptor in renal cell carcinomas. *International Journal of Cancer*, **1996**, 69, 212-7 | 7.5 | 112 |
| 85 | The HGF receptor family: unconventional signal transducers for invasive cell growth. *Genes To Cells*, **1996**, 1, 347-54 | 2.3 | 62 |
| 84 | The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation 1. *Journal of Biological Chemistry*, **1996**, 271, 6590-3 | 5.4 | 45 |
| 83 | Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. *Journal of Biological Chemistry*, **1996**, 271, 14119-23 | 5.4 | 121 |
| 82 | Control of Invasive Cell Growth by the Met Family Oncogenes **1996**, 23-43 | | |
| 81 | In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 1857-65 | 9.4 | 78 |
| 80 | Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. *Journal of Biological Chemistry*, **1995**, 270, 603-11 | 5.4 | 201 |
| 79 | Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. *Journal of Endocrinological Investigation*, **1995**, 18, 134-9 | 5.2 | 54 |
| 78 | Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions*1. *Hepatology*, **1995**, 21, 1543-1546 | 11.2 | 4 |
| 77 | Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. *Hepatology*, **1995**, 21, 1543-1546 | 11.2 | 31 |
| 76 | Structure and functions of the HGF receptor (c-Met) **1995**, 51-70 | | 1 |
| 75 | Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. *Journal of Cell Biology*, **1994**, 127, 1743-54 | 7.3 | 121 |
| 74 | Overexpression of the Met/HGF receptor in ovarian cancer. *International Journal of Cancer*, **1994**, 58, 658-62 | 7.5 | 197 |
| 73 | A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. *Cell*, **1994**, 77, 261-71 | 56.2 | 907 |
| 72 | Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. *Journal of Biotechnology*, **1994**, 37, 109-22 | 3.7 | 42 |

| | | | |
|---|---|---|---|
| 71 | Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues. *Brain Research*, **1994**, 637, 308-12 | 3.7 | 66 |
| 70 | Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 649-53 | 11.5 | 142 |
| 69 | Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. *British Journal of Cancer*, **1993**, 68, 746-50 | 8.7 | 165 |
| 68 | A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 11574-8 | 11.5 | 201 |
| 67 | Regional mapping of the human hepatocyte growth factor (HGF)-scatter factor gene to chromosome 7q21.1. *Genomics*, **1992**, 13, 912-4 | 4.3 | 22 |
| 66 | Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. *Cancer Genetics and Cytogenetics*, **1992**, 64, 170-3 | | 61 |
| 65 | The Receptor for the Hepatocyte Growth Factor-Scatter Factor: Ligand-Dependent and Phosphorylation-Dependent Regulation of Kinase Activity **1992**, 301-310 | | |
| 64 | Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. *Journal of Cellular Biochemistry*, **1991**, 45, 69-81 | 4.7 | 6 |
| 63 | The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. *International Journal of Cancer*, **1991**, 49, 323-8 | 7.5 | 269 |
| 62 | Ligand-independent tyrosine phosphorylation of the receptor encoded by the c-neu oncogene. *Growth Factors*, **1991**, 5, 233-42 | 1.6 | 5 |
| 61 | Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase. *Journal of Cellular Biochemistry*, **1990**, 42, 123-33 | 4.7 | 11 |
| 60 | Solubilization of the receptor for the neuropeptide gastrin-releasing peptide (bombesin) with functional ligand binding properties. *Biochemistry*, **1990**, 29, 5153-60 | 3.2 | 25 |
| 59 | Characterization of the detergent solubilized receptor for gastrin-releasing peptide. *Peptides*, **1990** , 11, 737-45 | 3.8 | 3 |
| 58 | Kinetics of tyrosine phosphorylation and internalization of human EGF receptors overexpressed in NIH 3T3 fibroblasts. *Experimental Cell Research*, **1990**, 191, 323-7 | 4.2 | 4 |
| 57 | Growth factor receptors and class 1 oncogenes in cancer. *Animal Genetics*, **1989**, 20, 348-50 | 2.5 | |
| 56 | Lipid characteristics of RSV-transformed Balb/c 3T3 cell lines with different spontaneous metastatic potentials. *Lipids*, **1989**, 24, 685-90 | 1.6 | 21 |
| 55 | Biochemical and immunological properties of the human carcinoma antigen CAR-5 defined by the monoclonal antibody BD-5. *International Journal of Cancer*, **1989**, 44, 67-74 | 7.5 | 8 |
| 54 | Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice. *Cancer Immunology, Immunotherapy*, **1989**, 29, 185-92 | 7.4 | 10 |

| | | | |
|---|---|---|---|
| 53 | Vanadate-treated baby hamster kidney fibroblasts show cytoskeleton and adhesion patterns similar to their Rous sarcoma virus-transformed counterparts. *Journal of Cellular Biochemistry*, **1988**, 37, 151-9 | 4.7 | 31 |
| 52 | Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line. *Journal of Cellular Biochemistry*, **1988**, 38, 229-36 | 4.7 | 12 |
| 51 | Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines. *Cancer Immunology, Immunotherapy*, **1988**, 27, 233-40 | 7.4 | 16 |
| 50 | A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas. *Annals of the New York Academy of Sciences*, **1988**, 547, 293-302 | 6.5 | 4 |
| 49 | Effect of the growth conditions on the expression of cell-surface-associated platelet-derived growth factor receptors in mouse fibroblasts. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1988**, 971, 351-7 | 4.9 | |
| 48 | Effect of the growth conditions on the expression of cell-surface-associated platelet-derived growth factor receptors in mouse fibroblasts. *Biochimica Et Biophysica Acta - Bioenergetics*, **1988**, 971, 351-357 | 4.6 | 2 |
| 47 | The tyrosine kinase associated with the bombesin receptor complex: Evidences for autocrine activation in small cell lung carcinomas. *Lung Cancer*, **1988**, 4, 190-195 | 5.9 | 1 |
| 46 | Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 2166-70 | 11.5 | 33 |
| 45 | Detection of deregulated tyrosine-kinases in experimental and human metastatic tumors. *Advances in Experimental Medicine and Biology*, **1988**, 233, 303-8 | 3.6 | |
| 44 | Interaction of fibroblasts, hemopoietic cells and platelets with extracellular matrix: characterization and role of a common cell surface glycoprotein. *Annals of the New York Academy of Sciences*, **1987**, 511, 65-76 | 6.5 | 1 |
| 43 | Protein tyrosine kinases associated with human malignancies. *Annals of the New York Academy of Sciences*, **1987**, 511, 256-61 | 6.5 | 14 |
| 42 | Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa. *European Journal of Cancer & Clinical Oncology*, **1987**, 23, 923-32 | | 5 |
| 41 | Proteins phosphorylated on tyrosine as markers of human tumor cell lines. *International Journal of Cancer*, **1987**, 39, 482-7 | 7.5 | 16 |
| 40 | Protein phosphorylation at tyrosine residues in v-abl transformed mouse lymphocytes and fibroblasts. *International Journal of Cancer*, **1986**, 37, 623-8 | 7.5 | 10 |
| 39 | Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral-oncogene-coded tyrosine kinases. *FEBS Journal*, **1986**, 158, 383-91 | | 33 |
| 38 | PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. *Biochemical and Biophysical Research Communications*, **1986**, 137, 343-50 | 3.4 | 47 |
| 37 | Bombesin stimulation of c-fos and c-myc gene expression in cultures of Swiss 3T3 cells. *Experimental Cell Research*, **1986**, 167, 276-80 | 4.2 | 45 |
| 36 | A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. *Experimental Cell Research*, **1986**, 163, 47-62 | 4.2 | 61 |

| | | | |
|---|---|---|---|
| 35 | In vivo phosphorylation and dephosphorylation of the platelet-derived growth factor receptor studied by immunoblot analysis with phosphotyrosine antibodies. *Biochimica Et Biophysica Acta - General Subjects*, **1986**, 881, 54-61 | 4 | 47 |
| 34 | Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. *Experimental Cell Research*, **1985**, 159, 141-57 | 4.2 | 359 |
| 33 | Organization of cytoskeleton and fibronectin matrix in Rous sarcoma virus (RSV)-transformed fibroblast lines with different metastatic potential. *European Journal of Cancer & Clinical Oncology*, **1985**, 21, 85-96 | | 8 |
| 32 | Role of heterochromatin variation in the instability of a marker chromosome during tumor progression. *Cancer Genetics and Cytogenetics*, **1985**, 15, 283-91 | | 13 |
| 31 | Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA. *Biochemical and Biophysical Research Communications*, **1985**, 132, 481-9 | 3.4 | 5 |
| 30 | Cleavage of a 135 kD cell surface glycoprotein correlates with loss of fibroblast adhesion to fibronectin. *Experimental Cell Research*, **1985**, 156, 182-90 | 4.2 | 96 |
| 29 | Monoclonal antibodies to the collagen binding domain of human plasma fibronectin. *Pathobiology*, **1984**, 52, 225-36 | 3.6 | 3 |
| 28 | Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line. *Biochemical and Biophysical Research Communications*, **1984**, 122, 563-70 | 3.4 | 25 |
| 27 | Immunofluorescence localization of phosphotyrosine containing proteins in RSV-transformed mouse fibroblasts. *Experimental Cell Research*, **1984**, 154, 112-24 | 4.2 | 25 |
| 26 | Metastatic clones selected from an RSV-induced mouse sarcoma share a common marker chromosome. *International Journal of Cancer*, **1983**, 31, 455-61 | 7.5 | 16 |
| 25 | Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas. *International Journal of Cancer*, **1983**, 31, 757-64 | 7.5 | 11 |
| 24 | Dissection of the antigenic determinants expressed on the cell surface of RSV-transformed fibroblasts by monoclonal antibodies. *International Journal of Cancer*, **1982**, 29, 477-81 | 7.5 | 6 |
| 23 | Mouse fibroblasts transformed by Rous sarcoma virus express a virus-specific non-virion transplantation antigen. *International Journal of Cancer*, **1981**, 27, 797-805 | 7.5 | 11 |
| 22 | Identification and partial characterization of five major membrane glycoproteins of BHK fibroblasts. *Journal of Membrane Biology*, **1980**, 53, 55-61 | 2.3 | 13 |
| 21 | Interaction between cellular and viral genes in the expression of the RSV-induced transformation-specific cell-surface antigen VCSA. *International Journal of Cancer*, **1980**, 25, 355-62 | 7.5 | 6 |
| 20 | Cell surface changes during muscle differentiation in vitro: a study with the probe 2,4,6-trinitrobenzene sulphonate. *Cell Differentiation*, **1979**, 8, 1-9 | | 6 |
| 19 | A virus-induced non-virion antigen specific for transformation at the surface of RSV-transformed fibroblasts. *Nature*, **1978**, 273, 381-3 | 50.4 | 11 |
| 18 | Tumor-specific and tumor-associated membrane antigens of Rous sarcoma virus transformed hamster fibroblasts. *International Journal of Cancer*, **1978**, 22, 55-62 | 7.5 | 5 |

| | | | |
|---|---|---|---|
| 17 | Immunochemical purification of probe-labeled plasma membrane proteins: an approach to the molecular anatomy of the cell surface. *Journal of Supramolecular Structure*, **1978**, 8, 39-49 | | 5 |
| 16 | Plasma membrane proteins exposed on the outer surface of control and Rous sarcoma virus-transformed hamster fibroblasts. *Experimental Cell Research*, **1977**, 110, 143-52 | 4.2 | 8 |
| 15 | A solid-state competitive binding radioimmunoassay for measurement of antigens solubilized from membranes. *Journal of Immunological Methods*, **1976**, 9, 267-72 | 2.5 | 17 |
| 14 | Binding of serum polypeptides to the plasma membrane outer surface. *FEBS Letters*, **1976**, 67, 364-7 | 3.8 | 14 |
| 13 | Involvement of sialic acids in the immunological specificity of plasma membrane glycoproteins. *Immunochemistry*, **1976**, 13, 97-102 | | 4 |
| 12 | Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes. *British Journal of Cancer*, **1976**, 34, 233-8 | 8.7 | 7 |
| 11 | Studies on the outer surface of normal and RSV-transformed BHK fibroblast plasma membrane. *Experimental Cell Research*, **1975**, 93, 402-10 | 4.2 | 15 |
| 10 | Antigenic and immunogenic properties of membrane proteins solubilized by sodium desoxycholate, papain digestion or high ionic strength. *Immunochemistry*, **1975**, 12, 9-17 | | 24 |
| 9 | Neuraminidase sensitive antigenic determinants of plasma cell tumor membrane glycoproteins. *FEBS Letters*, **1975**, 51, 351-4 | 3.8 | 6 |
| 8 | A comparative study of SV40-transformed fibroblast plasma membrane proteins labelled by enzymatic iodination or with trinitrobenzene sulfonate. *FEBS Letters*, **1974**, 47, 107-12 | 3.8 | 17 |
| 7 | Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts. *British Journal of Cancer*, **1974**, 30, 365-9 | 8.7 | 8 |
| 6 | Plasma-cell and tumor-associated membrane antigens of mouse plasmacytoma MOPC-315 and MOPC-460. *International Journal of Cancer*, **1973**, 12, 613-25 | 7.5 | 6 |
| 5 | Growth of syngeneic tumours in unimmunized newborn and adult hosts. *British Journal of Cancer*, **1973**, 27, 120-7 | 8.7 | 15 |
| 4 | Affinity chromatography purification of erythrocyte membrane proteins after selective labeling with trinitrobenzene sodium sulfonate. *Biochimica Et Biophysica Acta - Biomembranes*, **1973**, 311, 214-21 | 3.8 | 26 |
| 3 | Two dimensional distribution of concanavalin-A receptor molecules on fibroblast and lymphocyte plasma membranes. *FEBS Letters*, **1972**, 27, 256-8 | 3.8 | 41 |
| 2 | Antigen-dependent mast cell differentiation in vitro. *Experimental Cell Research*, **1972**, 72, 404-8 | 4.2 | 1 |
| 1 | Morphological and biochemical changes of rat prostate organ cultures and their reaction to prostate extracts. *Life Sciences*, **1971**, 10, 325-31 | 6.8 | |